CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Dacarbazinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00802880
NCT00802880Phase 2Completed
CompareCT.gov

Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma

Washington University School of Medicine·interventional·Posted Dec 5, 2008·Updated Feb 13, 2017

In Brief

A Phase 2 clinical trial evaluating Dacarbazine for Sarcoma. Completed, enrolled 80 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the overall best tumor response rate to dacarbazine given until disease progression as assessed by RECIST criteria, CT and clinical exams in patients with metastatic sarcomas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 5, 2008
Enrollment StartMar 1, 2009
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 17.6 years ago

Interventions

Dacarbazinedrug